<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Dimerix Limited ( (AU:DXB) ) 发布了公告。</p>
<p>Dimerix Limited 宣布根据员工激励计划发行 3,700,000 股未上市证券，这些证券不打算在 ASX 上上市。这一举措可能旨在激励员工，并使他们的利益与公司的增长保持一致，可能会影响公司的运营动态和利益相关者的参与。</p>
<p>关于 (AU:DXB) 股票的最新分析师评级为持有，目标价格为 A$0.50。要查看 Dimerix Limited 股票的完整分析师预测列表，请访问 AU:DXB 股票预测页面。</p>
<p><strong>关于 Dimerix Limited 的更多信息</strong></p>
<p>Dimerix Limited 在生物技术行业运营，专注于开发满足医疗需求的创新疗法。该公司主要从事药品的研究和开发，市场重点是解决慢性疾病。</p>
<p><strong>平均交易量：</strong> 1,175,581</p>
<p><strong>技术情绪信号：</strong> 强烈买入</p>
<p><strong>当前市值：</strong> A$345.2M</p>
<p>要深入了解 DXB 股票，请访问 TipRanks 的概览页面。</p>

<p>Dimerix Limited 已经在一项员工激励计划下发行了 3,700,000 份未上市证券，旨在激励员工并使其利益与公司的增长保持一致。这些证券不打算在澳大利亚证券交易所（ASX）上市。Dimerix（AU:DXB）的最新分析师评级为持有，目标价格为 0.50 澳元。Dimerix 主要从事生物技术，专注于慢性疾病的创新疗法</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Dimerix Limited ( (AU:DXB) ) has provided an announcement.</p>
<div class="lb-trans"><p>Dimerix Limited ( (AU:DXB) ) 发布了公告。</p>
</div><p>Dimerix Limited has announced the issuance of 3,700,000 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely aimed at incentivizing employees and aligning their interests with the company’s growth, potentially impacting the company’s operational dynamics and stakeholder engagement.</p>
<div class="lb-trans"><p>Dimerix Limited 宣布根据员工激励计划发行 3,700,000 股未上市证券，这些证券不打算在 ASX 上上市。这一举措可能旨在激励员工，并使他们的利益与公司的增长保持一致，可能会影响公司的运营动态和利益相关者的参与。</p>
</div><p>The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.</p>
<div class="lb-trans"><p>关于 (AU:DXB) 股票的最新分析师评级为持有，目标价格为 A$0.50。要查看 Dimerix Limited 股票的完整分析师预测列表，请访问 AU:DXB 股票预测页面。</p>
</div><p><strong>More about Dimerix Limited</strong></p>
<div class="lb-trans"><p><strong>关于 Dimerix Limited 的更多信息</strong></p>
</div><p>Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is primarily engaged in the research and development of pharmaceutical products, with a market focus on addressing chronic diseases.</p>
<div class="lb-trans"><p>Dimerix Limited 在生物技术行业运营，专注于开发满足医疗需求的创新疗法。该公司主要从事药品的研究和开发，市场重点是解决慢性疾病。</p>
</div><p><strong>Average Trading Volume:</strong> 1,175,581</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,175,581</p>
</div><p><strong>Technical Sentiment Signal:</strong> Strong Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 强烈买入</p>
</div><p><strong>Current Market Cap:</strong> A$345.2M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> A$345.2M</p>
</div><p>For an in-depth examination of DXB stock, go to TipRanks’ Overview page.</p>
<div class="lb-trans"><p>要深入了解 DXB 股票，请访问 TipRanks 的概览页面。</p>
</div>

Dimerix Limited 发行未上市证券以激励员工